

DESCRIPTION

Source *E. coli*-derived
Met1-His277, with an N-terminal Met and 6-His tag
Accession # AAA65015

N-terminal Sequence Analysis Not tested: Met predicted.

Structure / Form Pro form

Predicted Molecular Mass 33 kDa

SPECIFICATIONS

SDS-PAGE 35 kDa, reducing conditions

Activity The activity of the activated Caspase-3 was measured by its ability to cleave DEVD-AFC.
The specific activity is >500 pmol/min/μg, as measured under the described conditions. See Activity Assay Protocol on www.RnDSystems.com

Purity >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 μm filtered solution in Tris, NaCl, Sucrose and DTT. See Certificate of Analysis for details.

Activity Assay Protocol

- Materials**
- Assay Buffer: 20 mM Tris, 0.3 M NaCl, 0.05% (w/v) CHAPS, 5 mM DTT, 5% (w/v) Sucrose, pH 8.0
 - Recombinant Human Pro-Caspase-3 (rhPro-Caspase-3) (Catalog # 731-C3)
 - Recombinant Human Caspase-8 (rhCaspase-8) (Catalog # 705-C8)
 - Substrate: Ac-Asp-Glu-Val-Asp-AFC (MP Biomedicals, Catalog # AFC138), 10 mM stock in DMSO
 - F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
 - Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent

- Assay**
1. Activate rhPro-Caspase-3 at 10 μg/mL with 10 μg/mL rhCaspase-8 at a final concentration, respectively in Assay Buffer.
 2. Incubate reaction at 37 °C for 90 minutes.
 3. Dilute Substrate to 100 μM in Assay Buffer.
 4. Dilute Activated rhPro-Caspase-3 to 0.4 μg/mL.
 5. In a plate load 50 μL of 0.4 μg/mL rhPro-Caspase-3 and include a Substrate Blank containing 50 μL Assay Buffer.
 6. Start the reaction by adding 50 μL of 100 μM Substrate to wells.
 7. Read at excitation and emission wavelengths of 400 nm and 505 nm (top read), respectively in kinetic mode for 5 minutes.
 8. Calculate specific activity:

$$\text{Specific Activity (pmol/min/}\mu\text{g)} = \frac{\text{Adjusted } V_{\text{max}}^* \text{ (RFU/min)} \times \text{Conversion Factor}^{**} \text{ (pmol/RFU)}}{\text{amount of enzyme (}\mu\text{g)}}$$

*Adjusted for Substrate Blank

**Derived using calibration standard 7-amino, 4-(trifluoromethyl), Coumarin (Biomedicals, Catalog # 164580).

- Final Assay Conditions**
- Per Well:
- rhPro-Caspase-3: 0.02 μg
 - Substrate: 50 μM

PREPARATION AND STORAGE

Reconstitution Reconstitute at 50 μg/mL in 20 mM Tris, 300 mM NaCl, 5 mM Dithiothreitol, 5% Sucrose and 0.05% CHAPS, pH 8.0.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

- Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 6 months from date of receipt, -20 to -70 °C as supplied.
 - 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Caspase-3 (Cysteine-aspartic acid protease 3/Casp3; also Yama, apopain and CPP32) is a 29 kDa member of the peptidase C14A family of enzymes (1, 2, 3). It is widely expressed and is an integral component of the apoptotic cascade. Caspase-3 is considered to be the major executioner caspase; that is, the primary downstream mediator of apoptotic-associated proteolysis (2, 3, 4). Active Caspase-3 is known to utilize a Cys residue to cleave multiple substrates, including PARP, proIL-16, PKC- γ & - δ , procaspases 6, 7 and 9, and β -catenin (1). Human procaspase-3 is a 32 kDa, 277 amino acid (aa) protein (5, 6, 7). Normally, it is an inactive, cytosolic homodimer, but following an upstream signal that activates processing proteases, procaspase-3 undergoes proteolytic cleavage (1, 2, 8, 9). This generates an N-terminal 175 aa p20/20 kDa subunit plus a 102 aa C-terminal p12/12 kDa subunit, followed by further processing of the p20 subunit at Asp28 to generate a final p17 subunit (aa 29-175) (9). The p17 and p12 subunits noncovalently heterodimerize, and subsequently associate with another p17/p12 heterodimer to form an active antiparallel homodimer. The p17 subunit contains the enzyme active site (aa 161 - 165), with an embedded catalytic Cys which is normally nitrosylated and inactive. Full activation requires both proteolytic processing and Cys163 denitrosylation (10). Multiple proteases can use Caspase-3 as a substrate including Caspase-6, -8, and -10, granzyme B, and Caspase-3 itself (9, 11, 12, 13).

References:

1. Chowdhury, I. *et al.* (2008) *Comp. Biochem. Physiol. B* **151**:10.
2. Boatright, K.M. & G.S. Salvesen (2003) *Curr. Opin. Cell Biol.* **15**:725.
3. Launay, S. *et al.* (2005) *Oncogene* **24**:5137.
4. Walsh, J.G. *et al.* (2008) *Proc. Natl. Acad. Sci. USA* **105**:12815.
5. Nicholson, D.W. *et al.* (1995) *Nature* **376**:37.
6. Tewari, M. *et al.* (1995) *Cell* **81**:801.
7. Fernandes-Alnemri, T. *et al.* (1994) *J. Biol. Chem.* **269**:30761.
8. Milisav, I. *et al.* (2009) *Apoptosis* **14**:1070.
9. Han, Z. *et al.* (1997) *J. Biol. Chem.* **272**:13432.
10. Rossig, L. *et al.* (1999) *J. Biol. Chem.* **274**:6823.
11. Rank, K.B. *et al.* (2001) *Protein Expr. Purif.* **22**:258.
12. Atkinson, E.A. *et al.* (1998) *J. Biol. Chem.* **273**:21261.
13. Cohen, G.M. (1997) *Biochem. J.* **326**:1.